Search This Blog

Monday, January 7, 2019

CES 2019: AARP trialing virtual reality for remote healthcare


Can virtual reality serve as a remote medical diagnostic tool for seniors, who often have difficulty accessing quality healthcare? An ongoing collaboration between VRHealth, a healthcare technology company specializing virtual reality solutions and data analysis, and AARP Innovation Lab is testing the concept.
The idea is to use sensors and VR technology to enable remote health monitoring. VRHealth’s telehealth platform, available in the Oculus store, enables seniors to grant key participants in the medical process, like family members or physicians, access to healthcare data collected during VR therapy sessions. Caregivers are then able to make adjustments to treatment, potentially avoiding the need for a doctor’s visit.
Putting aside the low hanging jokes about my parents and their somewhat strained relationship with technology, the idea has a lot to recommend it. Mobility issues, money, and location constraints disproportionately conspire against seniors when it comes to accessing quality healthcare.
According to Pew Research, “nearly one-in-five (19%) Americans ages 65 and older say they had a medical problem but did not visit a doctor, skipped a medical test or a treatment recommended by a doctor, did not fill a prescription or skipped doses of their medicine because of cost constraints.”
While not a replacement for in-person treatment, a virtual connection to a healthcare provider could help mitigate some of the cost and mobility difficulties associated with establishing ongoing care.
“Our telehealth platform is a crucial step in the healthcare process because it enables patients to engage in a healthcare routine in the comfort of their own home while providing access to their data directly to their doctors,” VRHealth CEO Eran Orr says. “Any adjustments that need to be made to a patient healthcare regime can be adjusted based on the data in the platform.”

Potential pitfalls involved in beaming medical data over a network include the obvious digital privacy considerations, especially with vulnerable populations like older adults. There’s also the concern that caregivers could get an incomplete picture based on inbound data, resulting in improper treatment.
VRHealth is hoping to mitigate that likelihood with robust data collection and analysis. The company’s platform uses sophisticated tracking tools while the patient is engaged in VR therapy around several different use cases, including brain health applications, memory span and cognitive skills, neck exercises, and pain management techniques. As patients engage in directed activities in an immersive, 360-degree VR environment, vital data is collected, analyzed, and communicated with caregivers.
VRHealth has a residency at AARP Innovation Lab and is demoing the tele-health platform at AARP’s CES booth.
“AARP’s presence at CES is about highlighting how technology can increase social connections and improve people’s health, wealth and personal fulfillment,” said Andy Miller, AARP’s senior vice president of innovation and product development. “VR Health is exhibiting with us at CES since its VR platform helps foster crucial connections that seek to allow physicians, patients and their families to receive critical health information in real-time in order to provide the best possible care.”

Frequency Nabs $42M for Hearing Loss Drugs, Clinical Data On The Way


Hearing loss drug development continues to attract investment, with Frequency Therapeutics announcing today that it has brought in $42 million in a Series B financing to help it move its treatment through clinical testing.
Boston area-based Frequency is working on small molecule drugs that stimulate the growth of dormant stem cells in the body, and its lead drug, FX-322, targets key sensory cells in the inner ear. The drug, which is injected into the ear, is in an early-stage clinical trial, and the company says it will announce results in the first half of this year.
The new funding round was led by Taiwania Capital Management and Axil Capital, with Yonjin Capital and DF Investments also joining in as new investors. The round included investments from previous backers Polaris Founders Capital, Alexandria Venture Investments, Cobro Ventures, Korea Investment Partners, and Emigrant Capital.
Two other companies pursuing hearing loss treatments also secured funding in recent months. Decibel Therapeutics closed a $55 million Series C round last year, and says it should enter clinical testing this year with its drugs that protect against hearing loss that’s caused by other drugs. The company is also working on gene therapy for hearing loss.
Decibel isn’t alone in the gene therapy race. Akouos announced a $50 million funding round last year to finance its gene therapy for hearing loss, and the company’s leaders hope to start clinical trials in the next three years.

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs


Alector, a biotech company focusing on the immune system to treat degenerative brain disorders such as Alzheimer’s disease, has filed to go public to fund human tests of its experimental therapies.
South San Francisco, CA-based Alector set a preliminary $150 million target for its IPO. The company has applied for a listing on the Nasdaq exchange under the stock symbol “ALEC.”
In its prospectus, Alector challenges longstanding theories that point to problem proteins—amyloid beta and tau in Alzheimer’s, alpha-synuclein in Parkinson’s, and TDP-43 in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)—as the root causes of neurodegeneration. Alector contends that the underlying cause of neurodegeneration is a problem with immune cells in the brain.
Alector focuses on microglia, a type of immune cell that provides nourishment to neurons and “eats” cellular debris and pathological proteins. These cells can deteriorate with age, which in turn diminishes their ability to perform their beneficial and protective role, according to Alector. The company says its drugs target mutated genes linked to neurodegeneration, which could slow or even reverse the deterioration of the brain’s immune cells.
“By restoring healthy immune function in the brain, we believe we can simultaneously counteract the multiple pathologies responsible for neurodegeneration,” the company says in the filing.
Last year, Alector advanced two drugs into early-stage clinical testing. AL001 has been dosed in 42 FTD patients; the company reported no serious side effects or problems that would limit the dose of the drug. The company plans use the IPO proceeds to move on to a Phase 1b study, with data expected in the first half of this year. The second Alector drug, an experimental Alzheimer’s treatment called AL002, started a Phase 1 dose-escalating study in healthy patients.
Alector says the IPO proceeds will also be used to advance two other drugs into human testing: the Alzheimer’s drug AL003 and AL101, which is being assessed as a treatment for multiple neurodegenerative disorders.
The Alector Alzheimer’s drugs, AL002 and AL003, are being developed under a partnership with AbbVie (NYSE: ABBV). Under the agreement, AbbVie paid Alector $205 million up front and made a $20 million equity investment in its partner. Alector could gain up to $985 million more in milestone payments, depending on the progress of the Alzheimer’s drugs. Alector is responsible for Phase 1 and 2 testing. If AbbVie exercises its options on the drugs, the pharmaceutical giant will take over development and commercialization commercialization of the treatments, if they are approved for the market.
Alector, which was founded in 2013, has raised more than $210 million in financing, most recently a $133 million Series E round last year. Alector’s largest shareholders include affiliates of OrbiMed, which own 21.4 percent of the company, and affiliates of Polaris Venture Partners, which own 21.7 percent.

Prepping US move, OrbiMed-backed Apollomics bags $100M for I/O combos


Guo-Liang Yu has big plans mapped out for Apollomics in 2019: Move the biotech’s headquarters from Hangzhou, China to Foster City, CA; scout new assets to add to its pipeline, currently led by c-Met/PD-1 combo; and build up the team to run a trans-Pacific operation. With support from a well-heeled Chinese backer, he now has $100 million to bankroll all that.

OrbiMed Asia, where Yu is a partner, got the company started in 2016 with a modest $9.75 million Series A, back when it was named CBT Pharmaceuticals.
Like a number of players in the increasingly crowded checkpoint field, Apollomics is banking on a combination approach to immuno-oncology with partners including Beijing Pearl Biotechnology, Zhejiang Bossan Pharmaceutical, Genor Biopharma and Chia Tai TianQing.
The new cash will fund, and likely add to, the more than 10 ongoing clinical trials for these combos, which will be helped by an R&D facility and manufacturing capabilities built in Hangzhou in the past year.
Kexiang Zhou, managing director of CMBI, is joining the board.

Molina Healthcare upgraded to Overweight from Neutral at MUFG


https://thefly.com/landingPageNews.php?id=2845065

Danaher Q4 EPS seen at or near high end, revenue growth above prior guidance


Danaher Corporation announced that its president and Chief Executive Officer, Thomas P. Joyce, Jr., will comment tomorrow on the company’s fourth quarter 2018 performance in a presentation at the J.P. Morgan Healthcare Conference in San Francisco, California at 8:00 a.m. PT. Mr. Joyce will communicate that fourth quarter 2018 core revenue growth is expected to be above the company’s previously announced guidance and adjusted diluted net earnings per share is expected to be at or near the high-end of the previously announced guidance.
https://thefly.com/landingPageNews.php?id=2845067

MediciNova receives notice of allowance for new MN-001/002 patent in Japan


MediciNova announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001, or tipelukast, and MN-002 for the treatment of “fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover a composition for inhibiting or treating fibrosis using MN-001 or MN-002. The allowed claims cover oral administration including liquid and solid dosage forms.
https://thefly.com/landingPageNews.php?id=2845049